Bioequivalence,Bioassays,and Biowaivers: How Integrated Testing Can Accelerate Generic Drug Development

Abstract

Get full access to this article

View all access options for this article.

References

Nash

. The Use of Medicines in the United States: A Detailed Review. Am. Health Drug Benefits , 2012; 5(7): 423.

Patel

, Cholkar

, Agrahari

, Mitra

. Ocular drug delivery systems: An overview. World J. Pharmacol. , 2013; 2(2): 47–64.

Scoper

, Kabat

, Owen

, et al. Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension. Adv. Ther. , 2008; 25(2): 77–88.

Wang

, Black

. Ex vivo percutaneous absorption of ketamine, bupivacaine, diclofenac, gabapentin, orphenadrine, and pentoxifylline: comparison of versatile cream vs. reference cream. Int. J. Pharm. Compd. , 2013, 17(6): 520–525.

Food and Drug Administration. FDA Statement: Statement from FDA Commissioner Scott Gottlieb, M.D., on 2019 efforts to advance the development of complex generics to improve patient access to medicines. Released: January 30, 2019. Accessed: August 2, 2020. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-2019-efforts-advance-development-complex-generics.

Davit

, Kanfer

, Chung Tsang

, Cardot

J-M

. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements. AAPS J. , 2016; 18(3): 612–618.

Benet

. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J. Pharm. Sci. , 2013; 102(1): 34–42.